Lateral Flow Assays Market Regional Analysis:
APAC Market Insights
The Asia-Pacific lateral flow analysis market is predicted to hold the largest share of 34% during the assessment period. The Asia-Pacific region has a high burden of infectious diseases, which is driving the need for lateral flow testing for rapid and accurate diagnosis. Several countries in the Asia-Pacific region such as China and India are investing heavily in health infrastructure.
North American Market Insights
The North America lateral flow analysis market is assumed to hold a notable share of 26 % during the forecast period. North America is at the heart of technological advancements, driving the development of new and innovative transverse flow analysis technologies, and is anticipated to drive the growth of the market in the region.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of lateral flow assays is assessed at USD 10.3 billion.
The global lateral flow assays market size surpassed USD 9.76 billion in 2025 and is projected to witness a CAGR of around 6.2%, crossing USD 17.81 billion revenue by 2035.
Asia Pacific lateral flow assays market will secure around 34% share by 2035, driven by high burden of infectious diseases requiring rapid diagnosis.
Key players in the market include Abbott Laboratories, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., Danaher Corporation, F.Hoffmann-La Roche AG, QIAGEN N.V., Siemens Healthineers AG, Thermo Fisher Scientific, Inc., Merck kGaA, PerkinElmer Inc.
